podophyllotoxin has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castaldo, A; Fiorillo, A; Guarino, A; Guida, S; Migliorati, R; Poggi, V; Porta, F; Russo, S | 1 |
| Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H | 1 |
2 other study(ies) available for podophyllotoxin and Duncan Disease
| Article | Year |
|---|---|
Treatment of EBV-induced lymphoproliferative disorder with epipodophyllotoxin VP16-213.
Topics: Bone Marrow; Child, Preschool; Genetic Linkage; Herpesvirus 4, Human; Humans; Infectious Mononucleosis; Liver; Lymph Nodes; Lymphoproliferative Disorders; Male; Podophyllotoxin; Sex Chromosome Aberrations; X Chromosome | 1994 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Homologous | 2000 |